SCHEMBL2531130

SCHEMBL2531130

Cc1ccc(C(=O)O)c(C)c1OC(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
KDM4E B2RXH2 2/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 2/20 0.40
MAPT P10636 3/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
TEAD4 Q15561 1/20 0.37
HAAO P46952 1/20 0.36
TAS2R14 Q9NYV8 1/20 0.35
GRM1 Q13255 1/20 0.35
CYP1A2 P05177 1/20 0.34
TDP1 Q9NUW8 2/20 0.34
HTT P42858 1/20 0.34
TSHR P16473 2/20 0.33
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
MCL1 Q07820 1/20 0.33
NOTUM Q6P988 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8680142 0.85 HTT (0.33) ALDH1A1MAPTMEN1KMT2ATDP1
SCHEMBL8680145 0.83 ALDH1A1 (0.35) ALDH1A1MAPTMEN1KMT2A
SCHEMBL8679249 0.82 HTT (0.32) HTTRAB9A
SCHEMBL2495119 0.81 ALDH1A1 (0.38) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL1356924 0.80 ALDH1A1 (0.34) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL12569955 0.79 ALDH1A1 (0.60) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL11218412 0.78 TDP1 (0.50) ALDH1A1KDM4EHPGDHSD17B10MAPT
SCHEMBL13980116 0.77 MEN1 (0.33) ALDH1A1MAPTMEN1KMT2A
SCHEMBL8679253 0.77 ALDH1A1 (0.36) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL27667878 0.75 ALDH1A1 (0.39) ALDH1A1KDM4EMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1813613-B1 NOVEL FUSED IMIDAZOLE DERIVATIVE MSD KK (JP) 2012-12-19 EP disclosed
US-8030327-B2 3-[1-(2-chlorophenyl)ethoxy]-5-imidazo[1,2-a]pyridin-3-ylthiophene-2-carboxyamide; polo like kinase inhibitor; antitumor and anticarcinogenic agent; mitotic phase (M phase) of the cell cycle MDS K.K. (JP) 2011-10-04 US disclosed
US-20080103136-A1 Novel Fused Imidazole Derivative MSD K.K. (JP) 2008-05-01 US disclosed
EP-1813613-A1 NOVEL FUSED IMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103136-A1 Novel Fused Imidazole Derivative HRH4, H1-4, H1-3 ALDH1A1 1939/4885KDM4E 1299/4885HPGD 2599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.